Avalide Tablet, Film Coated
Product Images NDC 0024-5856

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Avalide (NDC 0024-5856). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1a (Avalide 01)

A line graph depicting the percentage of subjects with systolic blood pressure under 140 mmHg versus baseline systolic blood pressure (SBP) values ranging from 140 to 220 mmHg. The graph compares data from multiple studies (Study V and Study VI) with different treatment groups including average, irbesartan, and hydrochlorothiazide (HCTZ) groups, each represented by distinct line styles and colors.*

FDA Label Image

Figure 1b (Avalide 02)

A line graph showing the percentage of patients with systolic blood pressure (SBP) under 130 mmHg plotted against baseline SBP (mmHg). The chart compares data from different studies involving Avalide (irbesartan and hydrochlorothiazide) and their combinations in lowering blood pressure.*

FDA Label Image

Figure 2a (Avalide 03)

A line graph displaying the percentage of diastolic blood pressure (DBP) over 90 mmHg on the y-axis against baseline DBP in mmHg on the x-axis. The graph compares data from Studies V and VI for irbesartan (Irb) and hydrochlorothiazide (HCTZ) treatments, with distinct color-coded and patterned lines representing different study groups.*

FDA Label Image

Figure 2b (Avalide 04)

A line graph depicting the relationship between baseline diastolic blood pressure (DBP) and percentage DBP at 480 minutes for two studies, labeled Study V and Study VI. The graph includes multiple lines representing average values and individual treatment groups: Av. Study V, Irb. Study V, HCTZ Study V, Av. Study VI, and Irb. Study VI, with a legend identifying each line style.*

FDA Label Image

Chemical Structure (Avalide 05)

Chemical structure diagram of irbesartan, an active ingredient in the medication Avalide, showing its molecular framework with labeled rings and side chains.*

FDA Label Image

Chemical Structure (Avalide 06)

Chemical structure of irbesartan and hydrochlorothiazide, the active ingredients in Avalide tablets, film coated for oral use. The diagram shows atomic bonds and ring structures characteristic of the molecules.*

FDA Label Image

Figure 3 (Avalide 07)

A scatter plot with a curve illustrating the relationship between irbesartan dose (mg/day) on the x-axis and mmHg values on the y-axis. The graph shows the placebo-subtracted reduction in trough SeSBP, indicating increased blood pressure reduction with higher irbesartan doses up to about 900 mg/day.*

FDA Label Image

Figure 4 (Avalide 08)

A scatter plot with a fitted curve showing the placebo-subtracted reduction in trough SeDBP (diastolic blood pressure) versus Irbesartan dose in mg/day. The x-axis represents Irbesartan dose ranging from 0 to 900 mg/day, and the y-axis shows blood pressure reduction in mmHg, ranging from -2 to 8 mmHg. The data points are scattered with a curve indicating an overall increasing trend in blood pressure reduction as the Irbesartan dose increases.*

FDA Label Image

Principal Display Panel (150/12.5 mg Tablet Bottle Label)

Label for Avalide film-coated tablets containing irbesartan and hydrochlorothiazide 150 mg/12.5 mg. The label indicates a package of 30 oral tablets, labeled by Sanofi-Aventis U.S. LLC, with an origin of France. It includes storage information and a barcode.*

FDA Label Image

Principal Display Panel (300/12.5 mg Tablet Bottle Label)

Packaging label for Avalide tablets containing irbesartan and hydrochlorothiazide, strength 300 mg/12.5 mg, oral film-coated tablets. The label indicates a package size of 30 tablets and includes labeling by Sanofi-Aventis U.S. LLC, with NDC 0024-5856-30 and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.